Loading...

Intellectia LogoIntellectia
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
  1. Home
  2. Stock
  3. KLRA
KLRA logo

KLRA Overview

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewStock Price PredictionTechnicalValuationFinancialsEarningsShould I BuyNews & Events
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

Loading chart...

High
24.270
Open
22.520
VWAP
22.32
Vol
446.21K
Mkt Cap
2.53B
Low
21.220
Amount
9.96M
EV/EBITDA(TTM)
--
Total Shares
117.95M
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
Bcpe Perseus Investor LP, located in Delaware, a provider of financial investment services.
Show More

Events Timeline

(ET)
2026-04-22
08:20:00
PMV Pharmaceuticals Board Transition, Laurie Stelzer Appointed New Chair
select
2026-04-20 (ET)
2026-04-20
11:30:00
AEVEX Opens Above $20 in IPO Debut
select
2026-04-17 (ET)
2026-04-17
13:30:00
Kailera Therapeutics Prices 39.06M Shares at $16.00
select
2026-04-17
11:50:00
Kailera Therapeutics Increases Share Offering to 39.06M at $16.00
select
2026-04-17
10:40:00
Kailera Therapeutics Prices 39.06M Shares at $16.00
select
2026-04-17
05:00:00
Deal Size Increased to 39.06M Shares, Priced at High End of $16
select

News

Newsfilter
8.5
05-08Newsfilter
Odyssey Therapeutics Raises $279 Million in Upsized IPO
  • Upsized Fundraising: Odyssey Therapeutics successfully raised $279 million in its U.S. IPO by selling 15.5 million shares at $18 each, exceeding its expected range of $16 to $18, indicating strong market demand for biopharmaceutical companies.
  • Market Recovery Context: The U.S. biotech IPO market has seen a revival in 2026, driven by policy shifts under President Trump and significant FDA reforms, prompting several biotech firms, including Seaport Therapeutics and Kailera Therapeutics, to go public recently.
  • Research Focus: Odyssey is dedicated to developing treatments for autoimmune and inflammatory diseases, with its drug OD-001 currently in mid-stage trials for ulcerative colitis, highlighting its potential in the therapeutic landscape.
  • Planned Use of Proceeds: The company intends to allocate the proceeds primarily for the clinical development of OD-001 and for general corporate purposes, further advancing its research efforts and laying the groundwork for future market expansion.
renaissancecapital
8.5
05-01renaissancecapital
April IPO Market Rebounds with $7.3 Billion Raised
  • Significant Fundraising Surge: In April, 13 IPOs raised a total of $7.3 billion, with the latter half of the month seeing larger deals that pushed proceeds well above the historical average of $3.3 billion despite early volatility in March.
  • Large Deals Leading the Market: Twelve IPOs raised over $100 million, notably Madison Air (MAIR) completing the largest offering of the year, indicating strong demand for sizable projects in the current market.
  • Strong Investment Returns: Traditional IPOs averaged a robust 34% return by month-end, with nearly all trading above their issue price, reflecting a gradual restoration of market confidence in new listings.
  • Increased Market Activity: With IPO filings reaching a year-to-date high, improved market conditions and solid returns are encouraging more companies to prepare for listings, suggesting an acceleration of IPO activity in the coming weeks.
Fool
8.5
04-27Fool
RTW Investments Acquires Shares in Kailera Therapeutics
  • Acquisition Details: On April 20, 2026, RTW Investments acquired 500,000 shares of Kailera Therapeutics at $16.00 per share, totaling approximately $8 million, reflecting strong confidence in the company's potential.
  • Increase in Indirect Holdings: Following this transaction, RTW's indirect holdings rose to 10,776,820 shares while direct ownership remained at zero, indicating a strategic long-term investment approach towards Kailera.
  • Market Pricing Comparison: The acquisition price was significantly below the market close of $24.61 on April 20, 2026, suggesting that RTW benefited from favorable market conditions, potentially enhancing its investment returns.
  • Clinical Trial Progress: Kailera Therapeutics' dual agonist ribupatide demonstrated significant results in a clinical trial in China, with a 23.6% weight reduction after 36 weeks, laying a solid foundation for its future market performance.
Newsfilter
9.5
04-22Newsfilter
Hengrui Pharma Reports Steady Growth in Q1 2026
  • Significant Revenue Growth: Hengrui Pharma reported Q1 2026 revenue of RMB 8.14 billion, a 12.98% year-over-year increase, demonstrating strong market performance driven by innovative drugs.
  • Profit Increase: The net profit attributable to shareholders rose to RMB 2.28 billion, up 21.78%, reflecting enhanced profitability that provides robust financial support for future investments and R&D.
  • Increased R&D Investment: The company invested RMB 2.22 billion in R&D during Q1, representing 27.32% of revenue, indicating a strong commitment to its innovation-driven strategy aimed at advancing new drug development.
  • International Expansion Progress: Hengrui completed 12 overseas business development transactions, generating RMB 787 million in out-licensing revenue primarily from collaboration with GSK, further solidifying its competitive position in the global market.
Yahoo Finance
8.5
04-18Yahoo Finance
Kailera Therapeutics Prices IPO at $16.00
  • Increased Offering Size: Kailera Therapeutics has expanded its IPO share count from 33.3 million to 39.06 million shares, reflecting strong market confidence in its biotechnology prospects and is expected to generate higher funding to support its R&D efforts.
  • Successful Pricing Strategy: The IPO is priced at $16.00 per share, at the high end of the $14.00 to $16.00 range, indicating optimistic investor sentiment regarding the company's potential in obesity treatment, thereby enhancing market expectations for its future performance.
  • Strong Underwriter Lineup: The offering is backed by a robust consortium of underwriters including JPMorgan, Jefferies, Leerink, TD Cowen, and Evercore ISI, whose market influence and expertise are expected to effectively drive the success of the IPO.
  • Clear Strategic Focus: Kailera Therapeutics is dedicated to advancing the next generation of obesity care solutions, and as global obesity issues escalate, the company's innovations in biotechnology may present significant market opportunities and long-term growth potential.
renaissancecapital
8.5
04-17renaissancecapital
IPO Market Heats Up with $4.5 Billion Raised by Five Listings
  • Record Fundraising: This week, five companies raised a total of $4.5 billion in IPOs, including two deals exceeding $1 billion, highlighting a significant uptick in market activity, particularly with Madison Air Solutions leading at $2.233 billion, reflecting strong demand for indoor air quality technologies.
  • Strong Market Performance: Madison Air Solutions completed its IPO at the high end of pricing, achieving a market cap of $13.423 billion and a first-day return of 20%, indicating investor confidence in its air management technologies for data centers and commercial environments, which is expected to drive further market share growth.
  • Biotech Breakthrough: Kailera Therapeutics raised $625 million, setting a record for US biotech IPOs with a market cap of $2.021 billion, as its lead candidate is currently in global Phase 3 trials, showcasing its potential in obesity treatment, with a first-day return of 63%.
  • Growth in Defense Electronics: Arxis successfully raised $1.134 billion in its IPO, achieving a market cap of $11.633 billion; despite cyclical risks in aerospace and defense spending, its profitability and expanding free cash flow maintain its competitive edge, with a first-day return of 36%.
Wall Street analysts forecast KLRA stock price to rise
0 Analyst Rating
Wall Street analysts forecast KLRA stock price to rise
0 Buy
0 Hold
0 Sell
Current: 0.000
sliders
Low
Averages
High
Current: 0.000
sliders
Low
Averages
High
No data

No data

Valuation Metrics

The current forward P/E ratio for BCPE Perseus Investor LP (KLRA.O) is 0.00, compared to its 5-year average forward P/E of --. For a more detailed relative valuation and DCF analysis to assess BCPE Perseus Investor LP's fair value, Click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
Current PE
0.00
Overvalued PE
Undervalued PE

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
Undervalued EV/EBITDA

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
Current PS
0.00
Overvalued PS
Undervalued PS

Financials

AI Analysis
Annual
Quarterly

Whales Holding KLRA

Trading Trends

    Insider
    Hedge Fund
    Congress Trading

People Also Watch

Frequently Asked Questions

What is BCPE Perseus Investor LP (KLRA) stock price today?

The current price of KLRA is 21.47 USD — it has decreased -4.45

What is BCPE Perseus Investor LP (KLRA)'s business?

Bcpe Perseus Investor LP, located in Delaware, a provider of financial investment services.

What is the price predicton of KLRA Stock?

Wall Street analysts forecast KLRA stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for KLRA is USD with a low forecast of USD and a high forecast of USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

What is BCPE Perseus Investor LP (KLRA)'s revenue for the last quarter?

BCPE Perseus Investor LP revenue for the last quarter amounts to NaN USD, decreased

What is BCPE Perseus Investor LP (KLRA)'s earnings per share (EPS) for the last quarter?

BCPE Perseus Investor LP. EPS for the last quarter amounts to USD, decreased

How many employees does BCPE Perseus Investor LP (KLRA). have?

BCPE Perseus Investor LP (KLRA) has 0 emplpoyees as of May 10 2026.

What is BCPE Perseus Investor LP (KLRA) market cap?

Today KLRA has the market capitalization of 2.53B USD.